Gilead Sciences’ hepatitis C drugs, Sovaldi and Harvoni, will get exclusive coverage on several plans from CVS/Caremark, the pharmacy benefits manager said Monday, taking the opposite stance from competitor Express Scripts.

“Our goal was to create the lowest net-cost solution for the entire population of patients with all genotypes of hepatitis C,” CVS’ Cramer said in the statement. “When making this decision, we evaluated a wide variety of factors including duration of therapy, relative distribution of genotype and cost of the individual agents in the category as well as the results of a comprehensive clinical review of the different hepatitis C regimens.”

Just as if you put a frog in cool water and turns the heat up slowly… you end up with a dead BOILED FROG… If part of our healthcare system is allowed to “chip away” at the quality of available care and/or excludes choices of the prescriber… in treating their pts…  we get the best therapy available for the lowest cost to the system…

Will we end up with a healthcare system that only works well for the healthy ?